Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230036/S016

Esprit BTK RX System; Esprit BTK OTW System

ABBOTT MEDICAL · Decision date Oct 22, 2025

FDA DECISIONP230036/S016

What did the FDA decide?

FDA records P230036/S016 as a supplement to PMA P230036, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 22, 2025.

FDA approval order statement

approval for a change to the sponge used during the catheter lubricious coating application process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 22, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230036/S016
Regulatory pathway
PMA supplement
Product code
NXW
Decision code
OK30
Decision date
Oct 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Scaffold, infrapopliteal, absorbable.

Product code
NXW
FDA device class
3

For the original device and its historical approval scope, see PMA P230036. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230036 · Original PMA

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  2. P230036/S012 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  3. P230036/S013 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  4. P230036/S014 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  5. P230036/S015 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  6. P230036/S016 received

    Application receipt date recorded by FDA.

  7. P230036/S016 · FDA decision

    30-Day Notice

  8. P230036/S018 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  9. P230036/S017 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

  10. P230036/S020 · Related supplement

    Esprit BTK Everolimus Eluting Resorbable Scaffold System

Timeline entries are records held by MedtechLedger for P230036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230036

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records